The latest data of the DiviTum® assay as a unique efficacy marker of CDK4/6 inhibition is available on the American Association for Cancer Research (AACR) 2017 annual meeting website. Link to the results
Anders Rylander, CEO Biovica is interviewed in Analysguiden by Aktiespararna. The interview focus on the upcoming company IPO in march 2017. The interview is only available in Swedish.
Anders Rylander, CEO will present at the Vator Securities Unicorn Summit in Stockholm on March 7, 2017. The presentation, part of the company’s planned IPO on Nasdaq First North in March 2017, is intended for investors. The purpose of the IPO is to raise funds to initiate the commercialization phase of the company’s DiviTum™ [...]
Uppsala, Sweden, February 20, 2017. Biovica has strengthened its management team to ensure continued successful development. Cecilia Driving (CFO), Karin Mattsson (R&D Director) and Johanna Faris (Quality and Regulatory Assurance Director) have joined the company.
Uppsala, Sweden, February 16, 2017. The American Association for Cancer Research (AACR) Annual Meeting on April 1-5 will gather the world’s leading cancer researchers and oncologists. Together with its research partners Dana Farber Cancer Institute and the Karolinska Institute, Biovica will present new data on the company’s DiviTum™ assay as a response marker for CDK4/6 [...]
Anders Rylander, CEO of Biovica and Mattias Bergqvist, VP Marketing & Clinical Development discuss the challenges in cancer diagnostics, go-to-market strategies, clinical results and IPO preparations in the latest edition of Vatorpodden. The interview is available in Swedish (only)
Listen to Anders Rylander, CEO of Biovica and Mattias Bergqvist VP Sales & Marketing being interviewed in the latest edition of Vatorpodden. Anders and Mattias discuss the latest clinical results presented at the 2016 San Antonio Breast Cancer Symposium. The interview is available in Swedish (only)
Unique results show DiviTum™ is able to evaluate the anti-tumor activity of blockbuster cancer drug [Uppsala, Sweden, December 12, 2016] - New clinical study results presented at the San Antonio Breast Cancer Symposium, the world’s leading breast cancer conference, 6-10 December 2016, demonstrate that Biovica’s DiviTum™ biomarker assay can evaluate the efficacy of [...]
Biovica will attend the San Antonio Breast Cancer Symposium, an event that brings together oncology professionals from around the world. SABCS is the world’s leading breast cancer congress attracting more than 7,500 attendees from 90 countries. Read more at sabcs.org “At SABCS we will present new clinical study results in collaboration [...]
[Uppsala, Sweden, October 26, 2016]— Biovica and Eisai Inc. have entered into a lab services agreement to analyze DiviTum™, an assay measuring serum thymidine kinase, for improved drug evaluation in animal cancer models. In a preclinical setting at Eisai’s Andover innovative Medicine’s (AiM) Institute, Biovica’s non-invasive DiviTum™ technology will be used to test for evidence [...]